Immuneering Corporation (IMRX) saw its stock price rise by 3.06% to close at $2.02 on January 17th, following the release of promising data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The stock opened at $2.00, reached a high of $2.09, and a low of $1.93, with trading volume at 676,767 shares, which is 33.87% of the average. The positive momentum was driven by the announcement that the combination of IMM-1-104 with modified gemcitabine/nab-paclitaxel achieved an overall response rate of 43%, significantly surpassing the 23% benchmark from the Phase 3 MPACT study. Additionally, the disease control rate reached 86%, compared to 48% in the MPACT study. These results have generated optimism about the potential of IMM-1-104, with plans for future pivotal clinical trials.
The trial also revealed positive outcomes from the combination of IMM-1-104 with modified FOLFIRINOX, where all evaluable patients experienced tumor shrinkage, including one patient with a complete reduction. The treatment's differentiated tolerability profile and its Fast Track designation from the FDA for various cancer indications have further bolstered investor confidence. Immuneering's plans to expand its clinical trials in 2025, including new Phase 2a combination arms and trials in melanoma and non-small cell lung cancer, have also contributed to the positive sentiment.